Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 172

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

Open access
Nakai, Y, Isayama, H, Ijichi, H, Sasaki, T, Sasahira, N, Hirano, K, Kogure, H, Kawakubo, K, Yagioka, H, Yashima, Y, Mizuno, S, Yamamoto, K, Arizumi, T, Togawa, O, Matsubara, S, Tsujino, T, Tateishi, K, Tada, M, Omata, M, Koike, K · 2010 · British Journal of Cancer

Abstract

BACKGROUND: The renin-angiotensin system (RAS) is thought to have a role in carcinogenesis, and RAS inhibition may prevent tumour growth. METHODS: We retrospectively investigated the impact of angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) in 155 patients with pancreatic cancer receiving gemcitabine monotherapy. Patients were divided into three groups: the ACEI/ARB group (27 patients receiving an ACEI or ARB for hypertension (HT)), the non-ACEI/ARB with HT group (25 patients receiving antihypertensive drugs other than ACEIs or ARBs), and the non-HT group (103 patients receiving no antihypertensive drugs). RESULTS: Patient characteristics were not different, except for age and HT medications. Progression-free survival (PFS) was 8.7 months in the ACEI/ARB group, 4.5 months in the non-ACEI/ARB with HT group, and 3.6 months in the non-HT group. Overall survival (OS) was 15.1 months in the ACEI/ARB group, 8.9 months in the non-ACEI/ARB with HT group, and 9.5 months in the non-HT group. The use of ACEIs/ARBs was a significant prognostic factor for both PFS (P=0.032) and OS (P=0.014) in the multivariate analysis. CONCLUSIONS: The ACEIs/ARBs in combination with gemcitabine might improve clinical outcomes in patients with advanced pancreatic cancer. Prospective trials are needed to test this hypothesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6605955

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 172

Metadata

Authors
Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Sasahira, N., Hirano, K., Kogure, H., Kawakubo, K., Yagioka, H., Yashima, Y., Mizuno, S., Yamamoto, K., Arizumi, T., Togawa, O., Matsubara, S., Tsujino, T., Tateishi, K., Tada, M., Omata, M., & Koike, K.
Venue
British Journal of Cancer
Published
2010-10-26
Volume
103
Issue
11
Pages
1644-1648
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1992146834
Cited by
172
References
1
FWCI
4.42
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. https://app.cochat.ai/papers/10.1038/sj.bjc.6605955
The paper
Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Sasahira, N., Hirano, K., Kogure, H., Kawakubo, K., Yagioka, H., Yashima, Y., Mizuno, S., Yamamoto, K., Arizumi, T., Togawa, O., Matsubara, S., Tsujino, T., Tateishi, K., Tada, M., Omata, M., & Koike, K. (2010). Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605955

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.